Clinical evidences supporting the Src/c-Abl pathway as potential therapeutic target in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), the most common degenerative disease affecting motor neurons, lacks an effective disease-modifying disease treatment [1 –3]. Recently, the Src/c-Abl pathway has been postulated as a potential therapeutic target in ALS. [4]. Imamura et al. developed a phenotypic screen to repurpose existing drugs for ALS patients, which resulted in the identification of 27 potential hits. Intriguingly, more than half of the hits tar geted the Src/c-Abl signaling pathway [4]. Complementary studies demonstrated that Src/c-Abl inhibitors increased the survival of induced pluripotent stem cells (iPSC)-derived motor neurons from ALS patients in vitro.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Javier Riancho, Francisco J. Gil-Bea, David Castanedo-Vazquez, Mar ía José Sedano, Mónica Zufiría, Gorka Fernández Garcia de Eulate, Juan José Poza, Adolfo López de Munaín Tags: Letter to the Editor Source Type: research